Ebos Group Underperforms in Last 12 Months After Contract Loss, Management Shakeup, Jarden Says

MT Newswires Live06-03

Ebos Group (ASX:EBO, NZE:EBO) materially underperformed in the last 12 months after a change in group management and the loss of the Chemist Warehouse

contract prompted a reset in earnings expectations, Jarden said in a note on Tuesday.

Jarden trimmed its fiscal 2027 and fiscal 2028 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) estimates for the company after a review of the many moving parts mostly impacting the healthcare segment.

At the underlying net profit after tax level, the changes also reflect higher net interest costs and shifting Origin Biologics from an associate to non-controlling interest in fiscal 2027. Jarden assumed that in fiscal 2028, the company would acquire the remaining non-controlling interests, in line with its existing financial liability raised on the balance sheet for AU$38 million.

Near term, the healthcare segment is facing headwinds from fuel-related costs and ongoing competition in the community pharmacy segment, per the note.

The investment firm retained its overweight rating on Ebos Group and cut the price target to NZ$30.50 from NZ$33.80.

Ebos Group's Australian shares were down nearly 2% in recent Wednesday trade, while its Kiwi shares shed about 3%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640978872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640978872","market":"fut","top_or_hot":-1,"title":"Ebos Group Underperforms in Last 12 Months After Contract Loss, Management Shakeup, Jarden Says","media":"MT Newswires Live","content":"<html><body><p> Ebos Group (ASX:EBO, NZE:EBO) materially underperformed in the last 12 months after a change in group management and the loss of the Chemist Warehouse</p><p>contract prompted a reset in earnings expectations, Jarden said in a note on Tuesday.</p><p>Jarden trimmed its fiscal 2027 and fiscal 2028 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) estimates for the company after a review of the many moving parts mostly impacting the healthcare segment.</p><p>At the underlying net profit after tax level, the changes also reflect higher net interest costs and shifting Origin Biologics from an associate to non-controlling interest in fiscal 2027. Jarden assumed that in fiscal 2028, the company would acquire the remaining non-controlling interests, in line with its existing financial liability raised on the balance sheet for AU$38 million.</p><p>Near term, the healthcare segment is facing headwinds from fuel-related costs and ongoing competition in the community pharmacy segment, per the note.</p><p>The investment firm retained its overweight rating on Ebos Group and cut the price target to NZ$30.50 from NZ$33.80.</p><p>Ebos Group's Australian shares were down nearly 2% in recent Wednesday trade, while its Kiwi shares shed about 3%.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ebos Group Underperforms in Last 12 Months After Contract Loss, Management Shakeup, Jarden Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEbos Group Underperforms in Last 12 Months After Contract Loss, Management Shakeup, Jarden Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 10:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ebos Group (ASX:EBO, NZE:EBO) materially underperformed in the last 12 months after a change in group management and the loss of the Chemist Warehouse</p><p>contract prompted a reset in earnings expectations, Jarden said in a note on Tuesday.</p><p>Jarden trimmed its fiscal 2027 and fiscal 2028 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) estimates for the company after a review of the many moving parts mostly impacting the healthcare segment.</p><p>At the underlying net profit after tax level, the changes also reflect higher net interest costs and shifting Origin Biologics from an associate to non-controlling interest in fiscal 2027. Jarden assumed that in fiscal 2028, the company would acquire the remaining non-controlling interests, in line with its existing financial liability raised on the balance sheet for AU$38 million.</p><p>Near term, the healthcare segment is facing headwinds from fuel-related costs and ongoing competition in the community pharmacy segment, per the note.</p><p>The investment firm retained its overweight rating on Ebos Group and cut the price target to NZ$30.50 from NZ$33.80.</p><p>Ebos Group's Australian shares were down nearly 2% in recent Wednesday trade, while its Kiwi shares shed about 3%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBO.NZ","symbol_name":"Ebos Group Limited Ordinary Shares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640978872","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640978872","pubTimestamp":1780455429,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ebos Group  materially underperformed in the last 12 months after a change in group management and the loss of the Chemist Warehousecontract prompted a reset in earnings expectations, Jarden said in a note on Tuesday.Jarden trimmed its fiscal 2027 and fiscal 2028 underlying earnings before interest, taxes, depreciation, and amortization  estimates for the company after a review of the many moving parts mostly impacting the healthcare segment.At the underlying net profit after tax level, the changes also reflect higher net interest costs and shifting Origin Biologics from an associate to non-controlling interest in fiscal 2027. Jarden assumed that in fiscal 2028, the company would acquire the remaining non-controlling interests, in line with its existing financial liability raised on the balance sheet for AU$38 million.Near term, the healthcare segment is facing headwinds from fuel-related costs and ongoing competition in the community pharmacy segment, per the note.The investment firm ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"EBO.NZ":"Ebos Group Limited Ordinary Shares"},"translate_title":"Jarden表示，在合同损失和管理层改组后，Ebos集团在过去12个月中表现不佳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBO.NZ":1.5},"content_text":"Ebos Group (ASX:EBO, NZE:EBO) materially underperformed in the last 12 months after a change in group management and the loss of the Chemist Warehousecontract prompted a reset in earnings expectations, Jarden said in a note on Tuesday.Jarden trimmed its fiscal 2027 and fiscal 2028 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) estimates for the company after a review of the many moving parts mostly impacting the healthcare segment.At the underlying net profit after tax level, the changes also reflect higher net interest costs and shifting Origin Biologics from an associate to non-controlling interest in fiscal 2027. Jarden assumed that in fiscal 2028, the company would acquire the remaining non-controlling interests, in line with its existing financial liability raised on the balance sheet for AU$38 million.Near term, the healthcare segment is facing headwinds from fuel-related costs and ongoing competition in the community pharmacy segment, per the note.The investment firm retained its overweight rating on Ebos Group and cut the price target to NZ$30.50 from NZ$33.80.Ebos Group's Australian shares were down nearly 2% in recent Wednesday trade, while its Kiwi shares shed about 3%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640978872","isCrawlerRequest":true}